Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0530 · 6 trials · 8 indications
Number of responders (complete (CR) or partial (PR) responders). CR = disappearance of all target lesions PR = 30% decrease in the sum of the longest diamete. Analysis was based on August 31, 2009 data cut-off , and was performed with patients who had measurable disease and received AZD0530 175mg or Placebo 175mg.
Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.
| Arm | Type | Description |
|---|---|---|
| Active Comparator | ACTIVE_COMPARATOR | carboplatin plus paclitaxel |
| 2 | EXPERIMENTAL | AZD0530 in combination with carboplatin plus paclitaxel |
| AZD0530 175 mg | EXPERIMENTAL | AZD0530 (saracatinib) 175 mg once daily |
| Zoledronic Acid 4 mg | EXPERIMENTAL | Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period |
| 1 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | AZD0530 + Carboplatin + Paclitaxel |
| Name | Type | Description |
|---|---|---|
| AZD0530 | DRUG | oral once daily dose |
| Carboplatin | DRUG | intravenous injection |
| Paclitaxel | DRUG | intravenous infusion |
| Zoledronic Acid | DRUG | - |
| [14C] AZD0530 | DRUG | Solution, Oral, once |
Inclusion Criteria: * Have a diagnosis of advanced ovarian cancer * Have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy * Estimated life expectancy of more than 12 weeks Exclusion Criteria: * Central Ner...
Top 20 of 92 competitors
AZD0530 is an investigational small molecule being studied in oncology. Clinical trials have evaluated it in patients with breast cancer, prostate cancer with metastatic bone disease, solid tumors, and ovarian neoplasms. It has also been studied in healthy volunteers for formulation and metabolism research.
AZD0530 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company has sponsored clinical trials of the drug across multiple countries including the United States, Canada, Japan, and several European nations.
AZD0530 has completed Phase 2 clinical development. A Phase 2 trial in breast and prostate cancer patients with metastatic bone disease has been completed, along with Phase 1 studies in solid tumors and healthy volunteers. The drug remains investigational and is not approved.
AZD0530 has been studied in several completed trials. NCT00558272 was a Phase 2 study in breast and prostate cancer with metastatic bone disease. NCT00704366 was a Phase 1 study in Japanese patients with solid tumors. NCT00771979 and NCT00853983 were Phase 1 studies in healthy volunteers.
AZD0530 is also known as saracatinib. Clinical trial records reference the drug under the AZD0530 name, and it has been investigated as an oral agent in oncology settings including breast cancer, prostate cancer, and solid tumors.